Purple Biotech
PPBT
11 hedge funds and large institutions have $5.27M invested in Purple Biotech in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 4 closing their positions.
149% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $518K
42% more capital invested
Capital invested by funds: $3.72M → $5.27M (+$1.55M)
0% more ownership
Funds ownership: 0% → 0% (+0%)
8% less funds holding
Funds holding: 12 → 11 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.56M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$61K |
| 3 |
VVP
Venture Visionary Partners
Sylvania,
Ohio
|
+$48.4K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$22.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.19M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$245K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$137K |
| 4 |
O
OrbiMed
New York
|
-$86K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$83.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
1
ARK Investment Management
St. Petersburg,
Florida
| $3.37M | +$3.56M | +3,680 | New |
|
|
2
Point72 Asset Management
Stamford,
Connecticut
| $1.28M | -$1.19M | -1,229 | -47% |
|
|
3
Group One Trading
Chicago,
Illinois
| $214K | +$22.3K | +23 | +11% |
|
4
Morgan Stanley
New York
| $108K | -$69.7K | -72 | -38% |
|
|
CCM
5
Condor Capital Management
Martinsville,
New Jersey
| $96K | – | – | – |
|
|
WTB
6
Washington Trust Bank
Spokane,
Washington
| $75K | – | – | – |
|
|
7
Geode Capital Management
Boston,
Massachusetts
| $57K | +$61K | +63 | New |
|
|
VVP
8
Venture Visionary Partners
Sylvania,
Ohio
| $46K | +$48.4K | +50 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $19K | -$83.3K | -86 | -81% |
|
|
NSIM
10
North Star Investment Management
Chicago,
Illinois
| $1K | – | – | – |
|
|
SM
11
Sabby Management
Miami Beach,
Florida
| – | -$245K | -253 | Closed |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$137K | -141 | Closed |
|
|
O
13
OrbiMed
New York
| – | -$86K | -89 | Closed |
|
|
ASN
14
Advisory Services Network
Atlanta,
Georgia
| – | -$9K | -10 | Closed |
|
PPBT Hedge Fund Activity: Q3 2021 in Review
11 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q3 2021, worth a combined $5.27M — up 42% from $3.72M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PPBT and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was ARK Investment Management, opening a new position worth an estimated $3.56M. The largest seller was Point72 Asset Management, cutting an estimated $1.19M.
- 11 institutional investors held Purple Biotech (PPBT) as of Q3 2021, down from 12 in Q2 2021.
- Funds reported $5.27M of Purple Biotech stock for Q3 2021, up 42% quarter-over-quarter.
- 3 funds opened new Purple Biotech positions in Q3 2021 and 4 closed out, a net change of -1 holder.
- The largest Purple Biotech buyer in Q3 2021 was ARK Investment Management, an estimated $3.56M added.
- The largest Purple Biotech seller in Q3 2021 was Point72 Asset Management, an estimated $1.19M sold.
Based on aggregated 13F filings for Q3 2021.